Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Telix Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2025 was $2,862.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Telix Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $35.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Telix Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telix Pharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Telix Pharmaceuticals's EV-to-EBIT falls into.
Telix Pharmaceuticals's current Enterprise Value is $3,804.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Telix Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $35.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telix Pharmaceuticals (TLX) has a EV-to-EBIT of 108.23 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Telix Pharmaceuticals and its competitors. According to the industry distribution chart, Telix Pharmaceuticals ranks #349 out of 372 companies in the Biotechnology industry, placing it in the top 93.8%.
Is Telix Pharmaceuticals' EV-to-EBIT too high?
Telix Pharmaceuticals' current EV-to-EBIT is 108.23. The Biotechnology industry median EV-to-EBIT is 13.48. Telix Pharmaceuticals' value of 108.23 is 703.2% above this industry median. Based on the distribution chart, Telix Pharmaceuticals ranks #349 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Telix Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telix Pharmaceuticals ranks #349 out of 372 companies for EV-to-EBIT. This places Telix Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 13.48. Telix Pharmaceuticals' value of 108.23 is 703.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.48, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telix Pharmaceuticals's current EV-to-EBIT of 108.23 is 703.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Telix Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telix Pharmaceuticals's current EV-to-EBIT is 108.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (TLX) is currently considered Possible Value Trap. The stock's GF Value™ is $31.86, compared to a current price of $10.44 — trading 67.2% below its estimated fair value. The current EV-to-EBIT is 108.23 and 703.2% above the Biotechnology industry median of 13.48. Telix Pharmaceuticals' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Telix Pharmaceuticals (TLX), the current EV-to-EBIT is 108.23 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telix Pharmaceuticals (TLX) Overvalued in 2026?
Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued.
The current stock price of $10.44 is trading 67.2% below its estimated GF Value™ of $31.86.
GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for TLX:
EV-to-EBIT: 108.23
GF Value™: $31.86 vs. price of $10.44 (67.2% below fair value)
Industry Position: 703.2% above the Biotechnology median (#349 of 372)
No single metric tells the full story. See the TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
50GF Score
Get the complete analysis for TLX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLX has been successfully added to your 
